Protalix Biotherapeutics, Inc. (PLX)
1.82
+0.07
(+4.00%)
USD |
NYAM |
Dec 10, 16:00
1.82
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Cash from Investing (Quarterly): -0.504M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| GlucoTrack, Inc. | -0.067M |
| PAVmed, Inc. | -0.003M |
| AIM ImmunoTech, Inc. | 0.296M |
| Perspective Therapeutics, Inc. | 13.99M |
| Armata Pharmaceuticals, Inc. | -0.242M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.732M |
| Free Cash Flow | -11.69M |
| Free Cash Flow Per Share (Quarterly) | -0.0523 |
| Free Cash Flow to Equity (Quarterly) | -7.058M |
| Free Cash Flow to Firm (Quarterly) | -4.041M |
| Free Cash Flow Yield | -8.17% |